Bcl-2 plays a key role instead of mdr1 in the resistance to hexadecylphosphocholine in human epidermoid tumor cell line KB

Cancer Letters

Volumn 142, Issue 2, 1999, Pages 147-153

  Fu, Dong ^a   Shi, Zhao Xing ^a   Wang, Yu Zhi ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

bcl 2; Hexadecylphosphocholine; Multidrug resistance

Indexed keywords

COLCHICINE; MILTEFOSINE; VERAPAMIL; VINCRISTINE;

APOPTOSIS; ARTICLE; CELL STRAIN KB; CONTROLLED STUDY; EPIDERMOID TUMOR; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DRUG DESIGN; DRUG RESISTANCE; GENE EXPRESSION; GENES, BCL-2; GENES, MDR; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; ISOENZYMES; PHOSPHORYLCHOLINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0032974127     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00146-9     Document Type: Article

References (22)

1. Unger C., Damenz W., Fleer E.A., Kim D.J., Breiser A., Hilgard P., et al. Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and vivo. Acta Oncol. 28:1989;213-217.
2. Scherf H.R., Schuler B., Berger M.R., Schmahl D. Therapeutic activity of hexadecylphosphocholine against mammary tumors in BD-VI rats. Lipids. 22:1987;927-929.
3. Wang Y.Z., Chang Y.B., Xing C., Fu D. The interference effects of hexadecylphosphocholine on proliferation and membrane phospholipid metabolism in human myeloid leukemia cell lines. Tissue Reactions, XX (3):1998;101-107.
4. Kaufmann-Kolle P., Drevs J., Berger M.R., Kotting J., Marschner N., Unger C., et al. Pharmacokinetic behavior and antineoplastic activity of liposomal hexadecylphosphocholine. Cancer Chemother. Pharmacol. 34:1994;393-398.
5. Dummer R., Krasovec M., Roger J., Sindermann H., Burg G. Topical administration of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a phase I/II study. J. Am. Acad. Dermatol. 29:1993;963-970.
6. Safa O., Parkin S.M., Matthew A.M., Bibby M.C. Morphological and immunological observations on the effects of hexadecylphosphocholine (HPC) in nude mice bearing MT-1 breast cancer xenografts. Anticancer Res. 17:1997;37-43.
7. Small G.W., Strum J.C., Daniel L.W. Characterization of an HL-60 cell variant resistant to the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine. Lipids. 32:1997;715-723.
8. Fleer E.A.M., Berkovic D., Grunwald U., Hiddemann W. Induction of resistance to hexadecylphosphocholine in the highly sensitive human epidermoid tumour cell line KB. Eur. J. Cancer. 32:1996;506-511.
9. Twentyman P.R., Fox N.E., Rees J.K.H. Chemosensitivity testing of fresh leukemia cells using the MTT colorimetric assay. Br. J. Haematol. 71:1989;19-24.
10. Linn S.C., Kalken C.K., Tellingen O., Valk P.V.D., Groeningen C.J., Kuiper C.M., et al. Clinical and pharmacologic study of multidrug resistance reversal with vinblastine and bepridil. J. Clin. Oncol. 12:1994;812-819.
11. Rang H.P., Dale M.M. Pharmacology. 2nd edn. 1991;Churchill Livingstone Medical Division of Longman Group UK Limited. pp. 775.
12. Beketic-Oreskovic L., Duran G.E., Chen G., Dumontet C., Sikic B.I. Decreased mutation rate for cellular resistance to doxorubicin and suppression of mdr1 gene activation by the cyclosporin PSC 833. J. Natl. Cancer Inst. 45:1995;1593-1602.
13. Zhang X.H., Zhang F.Y., Ji X.J., Li Z.Y. Vincristine-resistance human KB cell line and mechanism of multidrug resistance. Acta Pharm. Sinica. 29:1994;246-251.
14. Raderer M., Scheithauer W. Clinical trials of agents that reverse multidrug resistance. Cancer. 72:1993;3553-3563.
15. Kanerva J., Tiirikainen M., Makipernaa A., Riikonen P., Mottonen M., Salmi T.T., et al. Multiple drug resistance mediated by P-glycoprotein is not a major factor in a slow response to therapy in childhood ALL. Pediatr. Hematol. Oncol. 15:1998;11-21.
16. Verdonck L.F., Heugten H.G. Ether lipids are effective cytotoxic drugs against multidrug-resistant acute leukemia cells and can act by the induction of apoptosis. Leuk. Res. 21:1997;37-43.
17. Reed J.C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol. 124:1994;1-6.
18. Engelmann J., Henke J., Willker W., Kutscher B., Nossner G., Engel J., et al. Early stage monitoring of miltefosine induced apoptosis in KB cells by multinuclear NMR spectroscopy. Anticancer Res. 16:1996;1429-1439.
19. Boggs K., Rock C.O., Jackowski S. The antiproliferative effect of hexadecylphosphocholine toward HL60 cells is prevented by exogenous lysophosphatidylcholine. Biochim. Biophys. Acta. 1389:1998;1-12.
20. Johnston J.B., Daeninck P., Verburg L., Lee K., Williams G., Israels L.G, et al. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. Leuk. Lymphoma. 26:1997;435-449.
21. Simonian P.L., Grillot D.A., Nunez G. Bcl-2 and Bcl-XL can differentially block chemotherapy-induced cell death. Blood. 90:1997;1208-1216.
22. Lindenboim L., Haviv R., Stein R. Inhibition of drug-induced apoptosis by survival factors in PC12 cells. J. Neurochem. 64:1995;1054-1063.